Sulfapyridine in the Treatment of Dermatitis Herpetiformis

Costello, Maurice J.

doi:10.1001/archderm.1947.01520110060008

Cited by 28 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…116,157 Thus in such cases, lower doses and closer follow-ups are recommended. 31,44,159 When methaemoglobinaemia levels are between 20% and 40%, symptoms such as dizziness, headache, tachycardia and 6 Alternative therapies in DH [164][165][166][167][168][169][170][171][172][173][174] Figure 5 Management of dermatitis herpetiformis (DH). Abbreviations: DIF, direct immunofluorescence microscopy; EMA, endomysial antibodies; TG2 EIA, tissue transglutaminase enzyme immunoassay; GFD, gluten-free diet; GI, gastrointestinal.…”

Section: Indications Of Dapsone Treatment In Dh Patientsmentioning

confidence: 99%

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

Görög

Antiga

Caproni

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Introduction Dermatitis herpetiformis (DH) is a chronic, pruritic, gluten‐induced skin disorder characterized by subepidermal granular IgA deposition and a variable degree of enteropathy identical to that seen in coeliac disease. So far, there has been no European consensus about the management of DH. Methods The guidelines were created by small subgroups of a guideline committee consisting of 26 specialists from various medical fields and one patients’ representative. The members of the committee then discussed the guidelines and voted for the final version at two consensus meetings. The guidelines were developed under the support of the European Academy of Dermatology and Venereology (EADV) and in collaboration with the European Dermatology Forum (EDF). Results The guidelines summarize evidence‐based and expert‐based recommendations (S2 level) for the management of DH (see Appendix). Conclusion These guidelines will improve the quality of management of DH and support dermatologists in their diagnostic and therapeutic decisions.

show abstract

Section: Indications Of Dapsone Treatment In Dh Patientsmentioning

confidence: 99%

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

Görög

Antiga

Caproni

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Variants The effect of sulfapyridine and sulfones on DH is dramatic. 17 Although the pharmacodynamic mechanisms are not under¬ stood,18 these drugs in appropriate dosage effect prompt relief from the intractable pruritus. Old lesions wane and new ones do not erupt.…”

Section: Commentmentioning

confidence: 99%

Papular Dermatitis Herpetiformis in Childhood

Ackerman¹

1969

Arch Dermatol

View full text Add to dashboard Cite

“…In 1947 Costello (1) reported the successful use of sulfapyridine in the treatment of dermatitis herpetiformis (DH). This led to the investigation of a number of different sulfonamides in the treatment of DH.…”

mentioning

confidence: 99%

Dapsone

Sago

Hall

2002

Dermatol Ther

View full text Add to dashboard Cite

Dapsone and other sulfonamides have been used successfully in the treatment of patients with a variety of blistering skin diseases. The patients most likely to respond to dapsone therapy have a predominantly neutrophilic infiltrate in their skin. Therefore the blistering diseases with the most consistent responses to dapsone therapy include dermatitis herpetiformis and linear IgA disease. Dapsone's precise mechanism of action is unknown. In vitro studies have shown that dapsone can interfere with the production of and response to neutrophil chemoattractants and that it may impair the neutrophils' ability to localize to sites of inflammation and produce toxic oxygen intermediates. The safe use of dapsone requires an understanding of the pharmacology and adverse effects of the drug. Hemolytic anemia and methemoglobinemia are two of the dose‐related adverse effects. Agranulocytosis, motor neuropathy, and dapsone hypersensitivity syndrome are some of the severe idiosyncratic effects that can occur in patients treated with dapsone. Dapsone is an effective drug for the management of patients with some blistering disease, especially those with predominant neutrophilic infiltrates in the skin. Careful patient selection and close monitoring of patients during therapy with dapsone are critical elements in the safe and effective use of dapsone for patients with blistering skin diseases.

show abstract

Sulfapyridine in the Treatment of Dermatitis Herpetiformis

Cited by 28 publications

References 15 publications

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

Papular Dermatitis Herpetiformis in Childhood

Dapsone

Contact Info

Product

Resources

About